Updated: US selects first 10 drugs subject to Medicare price negotiations
The US on Tuesday unveiled the first 10 drugs that will be subject to price negotiations under the Inflation Reduction Act, including several surprising additions that may face competition from generics before the negotiations start in 2026.
In total, the drugs racked up more than $50 billion in Medicare Part D spending from May 2022 to June of this year, and include three products from Johnson & Johnson as well as blockbusters from Bristol Myers Squibb, Eli Lilly, Merck and others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.